Latest News
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
2 November 2026 - INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced on Friday that the US Food a...
Fresenius and WuXi Biologics agree biosimilars development partnership
2 November 2026 - Healthcare company Fresenius SE & Co KGaA (XETR: FRE) (OTCM: FSNUY) declared on Monday that it has signed an exclusive development agreement with research, development and manufacturing contract organisation WuXi Biologics (2269...
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
2 November 2026 - US healthcare company Abbott (NYSE:ABT) on Sunday reported strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Device Exemption (IDE) Study evaluating the use of its ...
POLYTECH Health & Aesthetics partners with London Regenerative Institute on adipose tissue processing in aesthetic and reconstructive surgery
2 November 2026 - POLYTECH Health & Aesthetics GmbH, a Germany-based company involved in breast aesthetics, reconstruction, and body contouring, and the London Regenerative Institute (LRI), a clinician-led institute specialising in regenerative m...
Acumen Pharmaceuticals phase 2 Alzheimer's trial misses primary endpoint
30 October 2026 - Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company based in Newton, Massachusetts, on Friday said that initial topline results from its Phase 2 ALTITUDE-AD trial showed sabirnetug (ACU193) failed...